Engineering precision genetic medicine
Sarepta Therapeutics (sareptatherapeutics.com) scores 78 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 59th percentile of 11249 Healthcare brands.
Sarepta Therapeutics is a biopharmaceutical company headquartered in Cambridge, founded in 1980, that develops precision genetic medicines for rare neuromuscular and central nervous system diseases. The company focuses on shortening the drug development timeline, building large-scale gene therapy manufacturing capacity, and creating new access and reimbursement models. Its target audience includes patients and families affected by rare diseases, healthcare providers, and investors in the rare disease treatment space.
| Brand Name | Sarepta Therapeutics |
|---|---|
| Domain | sareptatherapeutics.com |
| Industry | Healthcare |
| Founded | 1980 |
| Headquarters | Cambridge |
| Main Competitors | PTC Therapeutics (85/100), Pfizer (89/100), Solid Biosciences (77/100), Regenxbio, Novartis (71/100), Biogen (78/100), BioMarin Pharmaceutical (84/100) |
Moz Domain Authority 43/100 vs category average 41 / leader 97 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta." (Meta description: 23 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:image, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, Drupal.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram, Facebook, YouTube; no detected presence on GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Sarepta Therapeutics?", Claude could identify the brand as of September 2026. Sarepta Therapeutics is a biotechnology company focused on developing gene therapies and RNA-based treatments for rare diseases, particularly Duchenne muscular dystrophy and other neuromuscular disorders. Best known for Developing treatments for Duchenne muscular dystrophy, including exon-skipping drugs like eteplirsen (Exondys 51) and gene therapy Elevidys.
When asked "Best brands similar to Sarepta Therapeutics?", Claude would recommend Sarepta Therapeutics as of September 2026. It's a leading and well-known name in rare disease gene therapy, especially for Duchenne muscular dystrophy, so it would naturally come up in relevant discussions.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Sarepta Therapeutics's main competitors in Healthcare: PTC Therapeutics (85/100), Pfizer (89/100), Solid Biosciences (77/100), Novartis (71/100), Biogen (78/100).
Sources: Brand Analyzer scan
Sarepta Therapeutics is a biopharmaceutical company founded in 1980 and headquartered in Cambridge. It focuses on developing precision genetic medicines to treat rare neuromuscular and central nervous system diseases.
Sources: Sarepta Therapeutics official site
Sarepta Therapeutics has limited AI-search visibility, scoring 29/100 on Brand Analyzer's AI visibility composite (visibility 23, trust 19, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Sarepta Therapeutics official site
Sarepta Therapeutics was founded in 1980. Sarepta Therapeutics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Sarepta Therapeutics is headquartered in Cambridge. Sarepta Therapeutics operates in the Healthcare category.
Sources: Wikidata
Sarepta Therapeutics develops precision genetic medicines aimed at treating rare neuromuscular and central nervous system diseases. Its work involves engineering genetic therapies, building large-scale gene therapy manufacturing capacity, and working to shorten the time between laboratory research and patient treatment. The company also seeks to develop new access and reimbursement models for these advanced therapies.
Sources: Sarepta Therapeutics official site
Sarepta Therapeutics scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Sarepta Therapeutics official site
Sarepta Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Sarepta Therapeutics official site
Sarepta Therapeutics offers precision genetic medicines targeting rare neuromuscular and central nervous system diseases. The company develops these treatments alongside manufacturing capacity for gene therapies and works on reimbursement and access frameworks for the therapies it develops.
Sources: Sarepta Therapeutics official site
Sarepta Therapeutics' offerings are intended for patients and families affected by rare neuromuscular and central nervous system diseases. Healthcare providers who treat these conditions and investors interested in the rare disease treatment sector are also part of its target audience.
Sources: Sarepta Therapeutics official site
Sarepta Therapeutics is known for its focus on precision genetic medicine for rare neuromuscular and central nervous system diseases, and for building what it describes as the world's largest gene therapy manufacturing capacity.
Sources: Sarepta Therapeutics official site
Sarepta Therapeutics scores 29/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Sarepta Therapeutics has a weak AI-visibility profile at 29/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is trust (19/100). It benefits from a Wikidata knowledge-graph entry, a Moz Domain Authority of 43/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Sarepta Therapeutics from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Sarepta Therapeutics: Sandstone Care (78/100), Sana Benefits (78/100), Sarms.io (78/100), SATO (78/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.